SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions, including encapsulation of live cells and services through their associate SG Austria, released additional information today about the therapeutic potential surrounding the recently described patent ownership for its ability to treat a wide array of cancers and other diseases through antibody and antibody-like protein therapy.
